^
    2ms
    First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor. (clinicaltrials.gov)
    P1/2, N=156, Not yet recruiting, Corbus Pharmaceuticals Inc.
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    CRB-601
    over1year
    CRB-601, an avβ8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment (AACR 2023)
    CRB-601 is a potent and selective integrin αvβ8 blocking monoclonal antibody that can overcome tumor immune exclusion and enhance the activity of immune checkpoint inhibitors. CRB-601 antitumor activity correlated to increased αvβ8 RO and downregulation of TGFβ signaling. Investigational New Drug (IND) enabling studies are in progress.
    Immune cell
    |
    IFNG (Interferon, gamma) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    CRB-601